 |
Patient's Own Infection-fighting T Cells Put Late-stage Melanoma Into Long-term Remission
|
| Researchers describe the first successful use of a human patient's cloned infection-fighting T cells as the sole therapy to put an advanced solid-tumor cancer into long-term remission. A team led by Cassian Yee, M.D., an associate member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, reports these findings in the June 19 issue of the New England Journal of Medicine.
|
| 6/19/2008
3:00 AM |
|
|
BioInvent And ThromboGenics Announce A Strategic Alliance With Roche For TB-403, A Novel Anti-Cancer Antibody
|
| BioInvent International AB (STO:BINV) and ThromboGenics NV (Euronext Brussels: THR) announce that they have entered into a license agreement with Roche (SWX: ROG) for their jointly developed anti-cancer agent TB-403. TB-403 is a novel monoclonal antibody which blocks Placental Growth Factor (PIGF), one of the growth factors responsible for the development of new blood vessels. Under the terms of the agreement effective from June 17, 2008 (or if a U.S.
|
| 6/19/2008
3:00 AM |
|
|
First Patient Dosed In A Phase 1 Clinical Trial With Oral TRC102, An Inhibitor Of Chemotherapy Resistance, In Combination With Alimta®
|
| TRACON Pharmaceuticals, Inc., announced that the first cancer patient has been treated in a Phase 1 clinical trial with oral TRC102, a novel anti-cancer drug intended to reverse resistance to Alimta® chemotherapy by targeting a specific DNA repair pathway. "TRACON is taking the lead in developing oral dosing of TRC102, which will provide better patient flexibility in treatments for advanced cancers.
|
| 6/19/2008
3:00 AM |
|
|
Talking About Sad, Bad And Difficult Issues In Cancer - ESMO And CRUK Partner On A Communication Skills Course For Oncologists
|
| An innovative course designed to help oncologists overcome communication barriers when talking to patients and their families will be organized in Buckinghamshire, UK from 18-20 June 2008 by the European Society for Medical Oncology (ESMO).
|
| 6/19/2008
2:00 AM |
|
|
ChemGenex's Omacetaxine Demonstrates Activity In CML Patients Who Have Failed Therapy With Multiple Tyrosine Kinase Inhibitors
|
| ChemGenex Pharmaceuticals (ASX:CXS) (NASDAQ:CXSP) announced the presentation of positive preliminary results from a phase 2 study of omacetaxine mepesuccinate (formerly known as Ceflatonin®) in chronic myeloid leukemia (CML) patients who have failed therapy with at least two tyrosine kinase inhibitors (TKIs). These data represent the first findings to be presented from this ongoing study, conducted in patients with or without BCR-ABL mutations.
|
| 6/19/2008
1:00 AM |
|
|
REVLIMID(R) Data For Newly Diagnosed Multiple Myeloma Reported At A Satellite Symposium During The 13th European Hematology Association Congress
|
| Data from the ECOG E4A03 and SWOG 0232 studies were reported at a Satellite Symposium and showed that newly diagnosed multiple myeloma patients who are eligible for a transplant, obtain better outcomes when treated with REVLIMID (lenalidomide) plus dexamethasone. The data were presented by Dr A. Stewart, from the Mayo Clinic at the 13th European Hematology Association (EHA) congress in Copenhagen, Denmark.
|
| 6/19/2008
1:00 AM |
|
|
Absence Of Viable Carcinoma In Biopsies Performed Greater Than 1-Year Following Radiofrequency Ablation Of Renal Cortical Tumors
|
| ORLANDO, FL (UroToday.com) - Stern and colleagues report on their experience with tissue biopsy more than 1 year after radiofrequency ablation (RFA) of small renal masses. The study included 19 patients with 20 renal masses (17 pre-treatment proven RCC and 3 oncocytomas) that had previously undergone RFA ablation, were stable in size on follow-up, and showed no evidence of enhancement on imaging. These lesions were percutaneously biopsied at a mean follow-up of 26.9 (13.1 - 58.0) months.
|
| 6/19/2008
12:00 AM |
|
|
Feds Crack Down On Fake Cancer Cures
|
| The US Food and Drug Administration (FDA) is cracking down on individuals and companies that market treatment products while fraudulently claiming them to be effective at preventing, treating or curing cancer. The FDA, a federal agency in the US government's executive Department of Health and Human Services, announced yesterday, 17th June, that it had sent "warning letters" to 23 US firms and two foreign individuals.
|
| 6/18/2008
10:00 AM |
|
|
Comment From Breakthrough Breast Cancer Re Alan Johnson Announcement This Afternoon That There Will Be A Review Into Co-Payment For NHS Services, UK
|
| Jeremy Hughes, Chief Executive of Breakthrough Breast Cancer says: "Today's announcement to review the policy on co-payments in the NHS is welcome news and should provide much needed clarity on this complex issue. "Breakthrough Breast Cancer believes that access to treatments should be based on clinical need and not cost. We look forward to hearing more about the proposed review and final report due in October."
|
| 6/18/2008
9:00 AM |
|
|
New Therapy Shows Promise For Fighting Treatment-Resistant Cancer Cells
|
| A gene radiotherapy system that detects and treats cancer cells that are resistant to traditional forms of chemotherapy and radiation showed success in the laboratory and could eventually prove beneficial for cancer patients, according to researchers at SNM's 55th Annual Meeting. The new system targets oxygen-deficient hypoxic cancer cells that have activated a gene known as HIF-1, which ensures the cells' survival and makes them unresponsive to most current treatments.
|
| 6/18/2008
7:00 AM |
|
|
Potential Of Targeted Therapies For Cancer
|
| A new study, presented at the SNM 55th Annual Meeting, shows the potential to pre-target the treatment of cancer cells - bringing personalized medicine one step closer from the laboratory to patients. By combining new molecular imaging techniques with targeted therapy, pretargeting offers cancer patients a more individualized treatment that can increase the effectiveness of therapies and minimize discomfort experienced during treatment.
|
| 6/18/2008
7:00 AM |
|
|
PET/CT Scan Could Be Valuable Noninvasive Tool For Determining Stages Of Ovarian Cancer
|
| Combined positron emission tomography (PET) and computed tomography (CT) scanning of patients in the early stages of ovarian cancer can enable physicians to determine whether the cancer has spread to nearby lymph nodes without having to perform surgery, according to researchers at the SNM's 55th Annual Meeting. As a result, unnecessary surgeries could be reduced, which would also lower morbidity rates and postoperative complications for ovarian cancer patients.
|
| 6/18/2008
7:00 AM |
|
|
New Study Shows Potential To Treat Or Prevent Viral Cancers
|
| A new study, presented at the SNM 55th Annual Meeting, shows that radioimmunotherapy (RIT) targeting viral antigens offers a novel option to treat - or even prevent - many viral cancers by targeting cancer cells expressing viral antigens or infected cells before they convert into malignancy.
|
| 6/18/2008
5:00 AM |
|
|
Decatur Memorial Hospital Becomes First In Illinois To Treat Cancer Patients With RapidArc" Radiotherapy Technology
|
| Decatur Memorial Hospital became the first medical center in Illinois, and the third in the United States, to treat a cancer patient using RapidArc" radiotherapy technology from Varian Medical Systems (NYSE: VAR). John Hosler, an 85-year-old prostate cancer patient, received his treatment in just under 90 seconds -- a treatment that would have taken 15-20 minutes using earlier treatment methods.
|
| 6/18/2008
5:00 AM |
|
|
After Genetic Testing People Obey Screening Recommendations Better
|
| When people know the results of genetic tests confirming they have inherited an increased risk of developing melanoma, they follow skin cancer screening recommendations more proactively - much like those who have already been diagnosed with the potentially deadly disease, according to results of a study completed at the University of Utah's Huntsman Cancer Institute and published in the June issue of Cancer Epidemiology, Biomarkers & Prevention.
|
| 6/18/2008
4:00 AM |
|
|
Wavelets Crunch Through Doctors' Day Long Struggle To Diagnose Brain Tumors
|
| Today if doctors devote a full day to analysis and expert thought, they may be able to provide just half a dozen patients with a diagnosis of the precise type of brain tumour they face. Now researchers at the University of Warwick have devised an automated technique that can give a preliminary analysis of the precise brain tumour type within seconds.Meningiomas are tumours of the brain and nervous system and they account for 20% of all brain tumours.
|
| 6/18/2008
4:00 AM |
|
|
Obesity-Related Cancer On The Rise
|
| As Americans' collective waistline has continued to expand, so has the prevalence of obesity-related cancer.According to the June issue of Mayo Clinic Health Letter, an estimated 14 percent of cancer deaths in older men and 20 percent in older women can be attributed to excess body fat. It's not fully understood why excess body fat increases the risk of cancer.
|
| 6/18/2008
4:00 AM |
|
|
Melanoma Risk - People Obey Screening Recommendations Better After Genetic Testing - Whether Or Not They Test Positive, Study
|
| When people know the results of genetic tests confirming they have inherited an increased risk of developing melanoma, they follow skin cancer screening recommendations more proactively - much like those who have already been diagnosed with the potentially deadly disease, according to results of a study completed at the University of Utah's Huntsman Cancer Institute and published in the June issue of Cancer Epidemiology, Biomarkers & Prevention.
|
| 6/18/2008
3:00 AM |
|
|
Champions Biotechnology Begins Preclinical Development Of Its Lead Oncology Drug Candidate
|
| Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, announced that it has begun preclinical development of the lead Benzoylphenylurea (BPU) sulfur analog compound that the Company acquired last year. The compound has shown promising activity against in vitro and in vivo models of prostate and pancreatic cancer.
|
| 6/18/2008
3:00 AM |
|
|
EMEA Recommends Information On Lung Cancer Cases To Be Included In Exubera Product Information, Europe
|
| The European Medicines Agency (EMEA) has recommended that the product information for Exubera be updated with new information on cases of lung cancer seen in patients taking the medicine. Exubera, from Pfizer Limited, is a fast-acting insulin powder for inhalation, used for the treatment of adults with type 1 or type 2 diabetes.
|
| 6/18/2008
1:00 AM |
|
|
Naviscan's PEM Flex" Detects Smallest Cancers Better Compared To MRI In An Independent Study
|
| Naviscan PET Systems®, a company specializing in organ specific high resolution PET scanners, announced today at the Society of Nuclear Medicine - new clinical data using the PEM Flex scanner in breast cancer management. The PEM Flex" Solo II is a commercially available, FDA cleared scanner that utilizes PET technology for the breast application known as positron emission mammography, PEM.
|
| 6/18/2008
1:00 AM |
|
|
MIT Researchers See Alternative To Common Colorectal Cancer Drug
|
| A compound that accumulates in cells more readily than a commonly used colorectal cancer drug may be just as useful in treating colorectal tumors, but with fewer side effects, MIT researchers have found. Both compounds are analogues of cisplatin, a potent anticancer agent, but the newly investigated compound, known as cDPCP, may better target colorectal cells, potentially sparing other body tissues from damage.
|
| 6/18/2008
12:00 AM |
|
|
Anti-Cancer Molecules Predicted By Computer
|
| A new computer-based method of analyzing cellular activity has correctly predicted the anti-tumour activity of several molecules. Research published in BioMed Central's open access journal Molecular Cancer describes 'CoMet' - a tool that studies the integrated machinery of the cell and predicts those components that will have an effect on cancer.
|
| 6/18/2008
12:00 AM |
|
|
American Cancer Society Program Helps Employers
|
| Newly published research conducted by the American Cancer Society and the University of Washington's Health Promotion Research Center finds the Society's Workplace Solutions consulting program to be successful in guiding employers to implement cost-effective chronic disease prevention strategies. The nonprofit Society considers the research validation of its unique ability to help employers control cost while improving access to affordable cancer prevention.
|
| 6/18/2008
12:00 AM |
|
|
Gene Therapy Improves Survival And Quality Of Life Of Dogs With Cancer
|
| A new gene therapy has helped pet dogs with cancer live longer and could potentially improve the quality of life and survival of people with cancer, said the therapy's developers. The results of the animal study will be presented at The Endocrine Society's 90th Annual Meeting in San Francisco.
|
| 6/17/2008
2:00 AM |
|
